exenatide vs semaglutide Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports GLP-1 single, dual, and triple

Dawn Ericsson, MD, a board-certified OB/GYN, alongside a clinical team experienced in peptide and metabolic therapy

Cancer Immunology, Immunotherapy

^Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program

However, the applicability of these findings may be limited as most studies were conducted in Western populations

Cilostazol modulates autophagic degradation of -amyloid peptide via SIRT1-coupled LKB1/ampk signaling in neuronal cells